ENLIVEN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.04 USD | +2.78% |
|
-4.45% | +52.02% |
| 06-11 | Baird Initiates Enliven Therapeutics With Outperform Rating, $32 Price Target | MT |
| 05-29 | Enliven Therapeutics, Inc. Appoints Lori Kunkel to the Committee | CI |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 570.4 | 989.7 | - | - |
| Enterprise Value (EV) 1 | 570.4 | 827.3 | 943.7 | 742 |
| P/E ratio | -6.89 x | -9.1 x | -7.36 x | -6.29 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | 59,367 x | 59,367 x |
| EV / Revenue | - | - | 56,608 x | 44,509 x |
| EV / EBITDA | -6.83 x | -6.89 x | -5.84 x | -3.53 x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 41,212 | 47,037 | - | - |
| Reference price 2 | 13.84 | 21.04 | 21.04 | 21.04 |
| Announcement Date | 14/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 0.0167 | 0.0167 |
| EBITDA 1 | - | - | -83.53 | -120 | -161.5 | -209.9 |
| EBIT 1 | - | -38.79 | -83.53 | -115.7 | -142.1 | -177.3 |
| Operating Margin | - | - | - | - | -852,167.55% | -1,063,413.32% |
| Earnings before Tax (EBT) 1 | - | -37.66 | -71.58 | -103.2 | -130.5 | -168.5 |
| Net income 1 | -24.74 | -37.66 | -71.58 | -103.2 | -130.5 | -168.5 |
| Net margin | - | - | - | - | -782,625.49% | -1,010,655.85% |
| EPS 2 | -3.170 | -3.560 | -2.010 | -2.312 | -2.858 | -3.348 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 10/11/22 | 21/03/23 | 14/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -16.42 | -20.13 | -24.25 | -22.73 | -25.99 | -28.26 | -30.5 | -30.96 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -14.72 | -16.72 | -20.77 | -19.37 | -22.74 | -26.09 | -27.8 | -29.15 |
| Net income 1 | -14.72 | -16.72 | -20.77 | -19.37 | -22.74 | -26.09 | -27.8 | -29.15 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -0.8000 | -0.4100 | -0.5100 | -0.4700 | -0.5400 | -0.5620 | -0.6160 | -0.6360 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/05/23 | 10/08/23 | 09/11/23 | 14/03/24 | 14/05/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 162 | 46 | 248 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | - | - | 0.72 | 0.9 | 1.13 |
| Capex / Sales | - | - | - | - | 5,368.93% | 6,754.65% |
| Announcement Date | 10/11/22 | 21/03/23 | 14/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
21.04
USD
Average target price
34
USD
Spread / Average Target
+61.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +52.02% | 990M | |
| +15.85% | 122B | |
| +18.91% | 113B | |
| +4.43% | 22.84B | |
| -18.63% | 20.72B | |
| -13.76% | 16.39B | |
| -16.61% | 16.51B | |
| -43.53% | 15.83B | |
| +1.75% | 13.49B | |
| +28.07% | 11.67B |
- Stock Market
- Equities
- ELVN Stock
- Financials Enliven Therapeutics, Inc.
